We advised the representatives of the several underwriters on the offering

Davis Polk advised the representatives of the several underwriters in connection with the public offering by Denali Therapeutics Inc. of 9,142,857 shares of common stock at $17.50 per share and pre-funded warrants to purchase 2,285,714 shares of common stock at $17.49 per pre-funded warrant, for an aggregate offering of $200 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “DNLI.”

Denali Therapeutics is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using its proprietary TransportVehicle platform. With a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, the company is advancing toward its goal of delivering effective medicines to transform the lives of people living with neurodegenerative, lysosomal storage and other serious diseases.

The Davis Polk corporate team included partners Alan F. Denenberg and Emily Roberts and associates Rebecca Lei, Alexander Curtis and Ashley Jaworoski. The intellectual property team included partner David R. Bauer and associate Emma Willems. The tax team included counsel Yixuan Long and associate Omar Hersi. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post